You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Extensively drug-resistant tuberculosis

LoBue, Philip

Current Opinion in Infectious Diseases:
doi: 10.1097/QCO.0b013e3283229fab
Respiratory infections: Edited by Michael S. Niederman
Abstract

Purpose of review: To describe the origin, epidemiology, diagnosis, treatment, prevention, and control of extensively drug-resistant tuberculosis (XDR TB).

Recent findings: XDR TB is defined as the occurrence of TB in persons whose Mycobacterium tuberculosis isolates are resistant to isoniazid and rifampin and to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). As of June 2008, XDR TB has been found in 49 countries including the United States. It generally takes several weeks to detect XDR TB using conventional culture-based methods, although some progress is being made in developing rapid molecular tests. Treatment for XDR TB is difficult, usually requiring at least 18–24 months of four to six second-line anti-TB drugs. Treatment success rates are generally 30–50%, with very poor outcomes in HIV-infected patients. Management of contacts to infectious XDR TB patients is complicated by the lack of a proven effective treatment for XDR latent tuberculosis infection.

Summary: XDR TB is an emerging global health threat. The disease is difficult and expensive to diagnose and treat, and outcomes are frequently poor. New rapid diagnostic tests and new classes of anti-TB drugs are needed to successfully combat this global problem.

Author Information

Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Correspondence to Philip LoBue, MD, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Mail Stop E-10, 1600 Clifton Road, Atlanta, GA 30333, USA Tel: +1 404 639 5348; fax: +1 404 639 8959; e-mail: plobue@cdc.gov

© 2009 Lippincott Williams & Wilkins, Inc.